Dr. Mohamed Algarni

Founding Section head, cancer control and outreach division

Consultant, Medical Oncologist.

Joint appointment assistant professor, COM.KSAU-HS

Director ,suspected cancer program

Department of oncology. King Abdulaziz medical city. National Guard Health affairs (NGHA). Riyadh. Saudi Arabia.

14 : 10 – 14 : 20

24 June | 2023 Day 2

Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study